Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid Stoffw Microb

Szkandera, J; Stotz, M; Absenger, G; Stojakovic, T; Samonigg, H; Kornprat, P; Schaberl-Moser, R; Alzoughbi, W; Lackner, C; Ress, AL; Seggewies, FS; Gerger, A; Hoefler, G; Pichler, M.
Validation of C-reactive protein levels as a prognostic indicator for survival in a large cohort of pancreatic cancer patients.
Br J Cancer. 2014; 110(1):183-188 Doi: 10.1038/bjc.2013.701 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG


Führende Autor*innen der Med Uni Graz
Pichler Martin
Szkandera Joanna
Co-Autor*innen der Med Uni Graz
Absenger Gudrun
Al-Zoughbi Wael
Gerger Armin
Höfler Gerald
Kornprat Peter
Lackner Karoline
Lembeck Anna Lena
Samonigg Hellmut
Schaberl-Moser Renate
Seggewies Friederike
Stojakovic Tatjana
Stotz Michael

Dimensions Citations:

Plum Analytics:

Scite (citation analytics):

Recent evidence indicates that the host inflammatory response has an important role in the tumour progression. Elevated C-reactive protein (CRP) levels have been previously associated with poor prognosis in several cancer types including small-scale studies in pancreatic cancer (PC) patients. The purpose of the present study was to validate the prognostic impact of plasma CRP levels at date of diagnosis on cancer-specific survival (CSS) in a large cohort of PC patients. Data from 474 consecutive patients with adenocarcinoma of the pancreas, treated between 2004 and 2012 at a single centre, were evaluated retrospectively. CSS was analysed using the Kaplan-Meier method. To evaluate the prognostic significance of plasma CRP levels, univariate and multivariate Cox analyses were applied. High plasma CRP levels at diagnosis were significantly associated with well-established prognostic factors, including high tumour stage and tumour grade and the administration of chemotherapy (P<0.05). In univariate analysis, we observed that a high plasma CRP level was a consistent factor for poor CSS in PC patients (hazard ratio (HR)=2.21; 95% confidence interval (CI)=1.68-2.92, P<0.001). In multivariate analysis, tumour stage, grade, administration of chemotherapy, a high neutrophil-lymphocyte ratio and the highest quartile of CRP levels (HR=1.60, 95% CI=1.16-2.21; P=0.005) were identified as independent prognostic factors in PC patients. In conclusion, we confirmed a significant association of elevated CRP levels with poor clinical outcome in PC patients. Our results indicate that the plasma CRP level might represent a useful marker for patient stratification in PC management.
Find related publications in this database (using NLM MeSH Indexing)
Aged -
C-Reactive Protein - metabolism
Carcinoma, Pancreatic Ductal - blood Carcinoma, Pancreatic Ductal - pathology
Cohort Studies -
Female -
Humans -
Kaplan-Meier Estimate -
Male -
Middle Aged -
Pancreatic Neoplasms - blood Pancreatic Neoplasms - pathology
Prognosis -
Proportional Hazards Models -
Reproducibility of Results -
Retrospective Studies -

Find related publications in this database (Keywords)
C-reactive protein
prognostic factor
pancreatic cancer
© Med Uni Graz Impressum